Financial items | 2022 | 2021 | 2020 |
---|---|---|---|
Current assets | 338,378 | 437,314 | 315,660 |
Non-current assets | 554,008 | 391,327 | 332,334 |
Total assets | 892,386 | 828,641 | 647,994 |
Current liabilities | 227,483 | 155,953 | 122,871 |
Non-current liabilities | 98,489 | 198,374 | 184,835 |
Total liabilities | 375,969 | 354,327 | 307,706 |
Share capital | 34,345 | 34,345 | 23,810 |
Other paid-in capital and Other components of equity | 105,393 | 104,691 | 20,284 |
Retained earnings | 376,179 | 334,827 | 295,816 |
Total equity | 516,417 | 474,314 | 340,288 |
- Home
-
Financial information
- Policies on safety and health and environment
- Environment management
- Environment system
- Safety and health management
- Education and training activities
- EHS certificates and awards
- Ethical management
- Code of ethics
- CP overview
- CP organization chart
- Coexistence Management
- Certificates
- Archives of fair trade
- Accessibility of pharmaceuticals
- Corporate social responsibility
- Awards
- Governance
- CSR Report
-
Financial information
- Policies on safety and health and environment
- Environment management
- Environment system
- Safety and health management
- Education and training activities
- EHS certificates and awards
- Ethical management
- Code of ethics
- CP overview
- CP organization chart
- Coexistence Management
- Certificates
- Archives of fair trade
- Accessibility of pharmaceuticals
- Corporate social responsibility
- Awards
- Governance
- CSR Report
Financial Information
Summary of Consolidated Statements of Financial Position
(Unit : KRW 1,000,000 / As of December 31, 2022)
Summary of Consolidated Statements of Comprehensive Income
(Unit : KRW 1,000,000 / As of December 31, 2022)
Financial items | 2022 | 2021 | 2020 |
---|---|---|---|
Revenue | 760,476 | 627,279 | 561,867 |
Cost of sales | 453,289 | 362,342 | 330,425 |
Gross profit | 307,187 | 264,937 | 231,442 |
Selling and administrative expenses | 208,879 | 184,343 | 155,949 |
R&D expenses | 41,705 | 39,146 | 35,506 |
Operating profit | 56,603 | 41,448 | 39,986 |
Finance income | 37,461 | 11,916 | 658 |
Finance costs | 21,375 | 5,156 | 4,204 |
Other income | 2,317 | 1,377 | 1,938 |
Other expenses | 11,980 | 4,320 | 2,334 |
Share of loss of associates | -4,154 | 25,453 | 0 |
Profit before income tax | 58,872 | 70,718 | 36,044 |
Income tax expense | 16,934 | 27,599 | 9,184 |
Profit for the year | 41,938 | 43,119 |
26,860 |
Total comprehensive income for the year | 48,796 | 44,409 | 25,494 |
Major financial ratio
(As of December 31, 2022)
Financial items | 2022 | 2021 | 2020 |
---|---|---|---|
Revenue growth rate | 21.23% | 11.64% | 7.17% |
Profit growth rate | -2.74% | 60.53% | -16.64% |
ROA | 4.87% | 5.84% | 4.65% |
ROE | 8.47% | 10.59% | 8.62% |
Debt ratio | 72.80% | 74.70% | 90.43% |
Reserve ratio | 1095.30% | 974.89% | 1242.40% |
Interest coverage ratio (times) | 9.24 | 9.26 | 11.96 |
Analysis on profitability
(As of December 31, 2022)
Financial items | 2022 | 2021 | 2020 |
---|---|---|---|
Gross profit margin | 40.39% | 42.24% | 41.19% |
R&D investment ratio | 6.09% | 6.64% | 6.32% |
Selling and administrative expenses ratio | 27.47% | 29.39% | 27.76% |
Operating profit margin | 7.44% | 6.61% | 7.12% |
Profit ratio for the year | 5.51% | 6.87% | 4.78% |